Johnson & Johnson (JNJ) earnings Q3 2026
Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday, driven by strong sales of its immune disease…
UnitedHealth Group (UNH) earnings Q3 2026
UnitedHealth Group signage on the floor of the New York Stock Exchange on April 21, 2025. Michael Nagle…
Novo’s Wegovy pill improves weight loss after switch from injections
People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…
Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since…
Lilly is ramping up future manufacturing for Foundayo obesity pill
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Healthcare stocks have caught fire, sending all 3 of our names to record highs
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
Eli Lilly launches program to boost employer coverage of obesity drugs
Eli Lilly on Thursday launched a new program designed to help more employers cover obesity drugs in the…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…